Seedlabs

Pay-for-Effectiveness Contract Addendum for Health AI

A contract template that ensures AI vendors only get paid if their tools actually improve patient outcomes.

An open-standard contract addendum plus independent verification that ties a health-AI vendor's payment and renewal pricing to measured local outcomes, making demonstrated effectiveness a condition of getting paid rather than a marketing claim.

MedicineArtificial Intelligence in Healthcare and Education
AI Governance and Cognitive ImpactHealthcare procurement and value-based contracting for AI tools

Concept

An open-standard contract addendum, plus a third-party verification service, that ties health-AI vendor payment to measured local outcomes. Terms are pre-registered at signing: for example, 80% of the license fee is fixed and 20% is released only when agreed outcome metrics (time-to-antibiotics, documentation minutes, no-show rates) improve beyond a threshold, measured by a neutral evaluator against the health system's own EHR data; renewal pricing steps up or down with sustained effect; and a clawback clause triggers if evaluation detects harm (e.g., added clinician workload with no outcome gain). Publishing the addendum as an open standard lets any health system or group purchaser adopt identical terms, and the independent verification gives both sides a measurement they can contract against without trusting the vendor's own dashboard. The wedge: use purchasing power — not new regulation — to make effectiveness evidence a condition of revenue.

Why now

The JAMA Summit [0] names as its fourth priority "an incentive structure... using market forces and policy levers," observing that evaluations are often "not required, in part because many [tools] are outside the US Food and Drug Administration's regulatory oversight" — meaning vendors today have no financial reason to prove effectiveness. Corpus work argues the practical path is incremental: work "within the existing legal and regulatory schemes which allocate responsibility, and therefore liability, to persons" [6], and contracting is the most direct liability-allocating lever purchasers already control; the cross-industry policy review confirms formal AI regulation remains fragmented and uneven across sectors [1]. With scribing, imaging, and business-operations AI already widely adopted [0], there is a large base of renewals to re-paper, and performance-based terms are a proven purchasing pattern in adjacent markets such as pharmaceuticals.

Written by GLM · 9 Oct 2026

AI assessment

Backed by 3 papers79

A pragmatic, market-driven approach to AI accountability that leverages procurement power rather than waiting for regulation, though it faces significant friction in vendor adoption.

Evidence strength
4/5
The idea directly addresses the JAMA Summit's call for incentive structures and market-based levers to replace missing FDA oversight for many AI tools.
Market pull
4/5
Health systems (like Intermountain) have high urgency to justify AI spend and reduce 'pilot fatigue,' making them strong buyers of a verification and contracting standard.
Novelty & moat
3/5
While it shares a data-driven evaluation core with the 'Rapid Local Effectiveness Trials' idea, it shifts the value proposition from 'insight' to 'financial enforcement' via a contract addendum.
Feasibility
3/5
The technical verification is feasible, but the primary hurdle is the legal and commercial negotiation required to get vendors to sign performance-based contracts.
Wedge clarity
5/5
The 'contract addendum' is a sharp, specific entry point that targets the procurement process rather than attempting to build a broad clinical platform.
Simplicity / focus
5/5
The product is focused on a single, clear mechanism: tying payment to verified outcomes through a standardized legal and technical bridge.

Scored by Gemma 4 · 9 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Premier Inccompany

    The group purchasing organization negotiates contracts for thousands of hospitals; an open outcome-linked addendum lets it re-paper AI renewals with terms that protect members from paying for unproven tools.

  • Intermountain Healthcareorganization

    A long-time value-based-care innovator that can pilot outcome-linked AI contracts across its hospitals and publish the template for the rest of the sector.

  • Abridgecompany

    An ambient-documentation vendor confident in its effect on clinician time could accept outcome-linked terms to win enterprise deals against competitors unwilling to be measured.

  • Centers for Medicare & Medicaid Servicesorganization

    Could reference outcome-linked terms in coverage of AI-enabled services, creating the policy-side pull for effectiveness evidence that the JAMA Summit calls for.

Research it builds on

  1. AI, Health, and Health Care Today and Tomorrow
    Derek C. Angus, Rohan Khera, Tracy A. Lieu et al. · 2025 · 181 citations
    All ideas from this paper →
  2. How should we regulate artificial intelligence?
    Chris Reed · 2018 · 113 citations
    All ideas from this paper →
  3. Policies and regulations of artificial intelligence in healthcare, finance, agriculture, manufacturing, retail, energy, and transportation industry
    Nitin Liladhar Rane, Jayesh Rane, Mallikarjuna Paramesha et al. · 2024 · 21 citations
    All ideas from this paper →
Leave feedback
feasibility